CD8A and neoplasm: While we demonstrate that Mam-A2.4 is the most efficacious epitope, being able to sustain the anti-tumor response the longest, we recognize that due to the limitations of our model system (i.e., the immunodominant epitope could be influenced by impaired coreceptor interactions due to murine CD8 not being able to interact normally with human HLA class I molecules) that this might not translate directly into the clinical setting.